TickerKhojPharmaceuticals · Pharmaceuticals: Major · NSE: BAFNAPH · data 2026-11-02
Bafna Pharmaceuticals Limited
In plain words
Price: 6.7% below its 52-week high of ₹479.95.
Delivery: 79.1% of traded shares were kept for delivery over the last 10 sessions, against 76.5% over the last 47.
Latest results: a net profit of ₹0 cr for the quarter ended Jun 2026 (-97.6% on the same quarter a year earlier).
A description of the data, not a recommendation.
Key figures
Growth
| Revenue (last 12 months) | ₹143 cr |
| Net profit (last 12 months) | ₹8 cr |
| Sales growth, 3 years (yearly) | 9.3% |
| Profit growth, 3 years (yearly) | -0.7% |
At a glance
Promoters 75.0% (unchanged in a year), pledged 0.0%, institutions 9.3%.
P/E 136.1, dividend yield 0.0%. Price relative to earnings and book value (low is cheaper, not better).
ROE 12.3%, ROCE 9.2%, operating margin 3.7%: how much profit it earns on the money it uses.
Debt/equity 0.39, Profit growth -0.7% and sales growth 9.3% a year over 3 years.
Ratings use fixed thresholds on the latest reported figures. They describe the numbers and are not a recommendation.
Strengths and limitations
None flagged by these rules.
- Thin operating margin (3.7%).
- Profit fell 0.7% a year over 3 years.
- Expensive on earnings (P/E 136.1).
Picked automatically from the latest reported figures with fixed rules; check the company's filings before relying on them.
Latest results in brief (Q1 FY27)
Q1 FY27
Revenue: 26.58
Net Profit: 0.08
Operating Margin: 3.3
EPS: 0.03
Q1 FY27
राजस्व: 26.58
नेट लाभ: 0.08
परिचालन मार्जिन: 3.3
EPS: 0.03
Q1 FY27
મહેસૂલ: 26.58
નેટ લાભ: 0.08
કાર્યક્ષમ માર્જિન: 3.3
EPS: 0.03
Written by AI from the filed numbers and checked against them. Not a recommendation.
Smart-money activity
5/100 · Weak over the last ~60 sessions, data 2026-10-30
- Delivery vs usual 0/30: Too few delivery days to compare delivery % (0 of 10); shares delivered not comparable (0 of 12); 0 delivery-spike days (3x usual shares delivered, 40%+ delivery) in the last 20 sessions.
- Bulk/block deals 0/20: No bulk or block deals in the last 90 days.
- Insider / SAST buys 0/15: No insider buy or SAST acquisition filings in the last 90 days. Insider sells are not collected by the site, so only buy filings count.
- Mutual fund holding 0/15: No mutual fund scheme lists this stock. Latest monthly portfolios only (top 60 holdings per scheme); month-on-month change is not stored.
- Accumulation evidence 0/15: No accumulation evidence row (only saved-scan stocks have one; 0 points).
- Promoter pledges 5/5: No promoter pledge filings in 90 days.
A description of recorded activity (delivery, deals, insider buys, fund holding, pledges), not a recommendation. Today's most active stocks.
Story so far
● Results
- 11 Aug 26Results Q1 FY27 results: profit −97.6% YoY -3.9% next session
- 29 May 26Results Q4 FY26 results: profit +109.9% YoY +6.6% next session
- 11 Feb 26Results Q3 FY26 results: profit +93.7% YoY -3.2% next session
- 11 Nov 25Results Q2 FY26 results: profit +19.1% YoY +2.9% next session
- 12 Aug 25Results Q1 FY26 results: turned to profit vs a year ago +8.2% next session
- 26 May 25Results Q4 FY25 results: profit −10.3% YoY +1.5% next session
- 7 Feb 25Results Q3 FY25 results: turned to profit vs a year ago -1.9% next session
- 12 Nov 24Results Q2 FY25 results: profit +5.6% YoY -3.6% next session
From official exchange filings and NSE data. How the price moved after an event describes the past, not what comes next.
Quarterly results (standalone)
| Quarter | Revenue | Net profit | Profit YoY | Op. margin | EPS ₹ |
|---|---|---|---|---|---|
| Jun 2026 | ₹27 cr | ₹0 cr | -97.6% | 3.3% | 0.03 |
| Mar 2026 | ₹42 cr | ₹3 cr | +109.9% | 8.4% | 1.16 |
| Dec 2025 | ₹38 cr | ₹2 cr | +93.7% | 8.0% | 0.78 |
| Sept 2025 | ₹35 cr | ₹3 cr | +19.1% | 12.1% | 1.32 |
Shareholding trend
| Holder | Sept 2026 | Jun 2026 | Mar 2026 | Dec 2025 |
|---|---|---|---|---|
| Promoters | 75.00% | 75.00% | 75.00% | 75.00% |
| Foreign institutions (FII) | 9.34% | 9.34% | 9.34% | 9.34% |
| Domestic institutions (DII) | — | — | — | — |
| Mutual funds | — | — | — | — |
| Retail investors | 5.48% | 4.98% | 4.48% | 4.48% |
| Number of shareholders | 6,810 | 7,062 | 6,928 | 7,119 |
Common questions
What was Bafna Pharmaceuticals Limited's latest quarterly profit?
Bafna Pharmaceuticals Limited reported a net profit of ₹0 cr for the quarter ended Jun 2026 (-97.6% on the same quarter a year earlier), on revenue of ₹27 cr.
How much do promoters hold in Bafna Pharmaceuticals Limited?
Promoters held 75.00% of Bafna Pharmaceuticals Limited at the end of Sept 2026, with 0.00% of promoter shares pledged.
Is Bafna Pharmaceuticals Limited debt-free?
Its latest reported debt-to-equity ratio is 0.39.
What is Bafna Pharmaceuticals Limited's P/E ratio?
About 136.1, based on the last 12 months' earnings and a price of ₹447.9 (data 2026-11-02).
What is the 52-week high and low of Bafna Pharmaceuticals Limited?
The 52-week high is ₹479.95 and the 52-week low is ₹94.77.
Compared with similar companies
| Company | Price | Market cap | P/E | P/B | ROE | ROCE | Debt/eq. | 1-yr return |
|---|---|---|---|---|---|---|---|---|
| Bafna Pharmaceuticals Limited | ₹447.9 | ₹1,060 cr | 136.1 | — | 12.3% | 9.2% | 0.39 | +218.1% |
| Kopran Limited | ₹244.01 | ₹1,156 cr | 47.2 | — | 4.9% | 10.1% | 0.29 | +47.4% |
| Bajaj Healthcare Ltd | ₹308.3 | ₹1,031 cr | 51.8 | 1.9 | 4.3% | 13.2% | 0.47 | -36.6% |
| Sigachi Industries Limited | ₹25.84 | ₹1,009 cr | 38.9 | — | -14.6% | 6.1% | 0.31 | -30.0% |
| Lincoln Pharmaceuticals Ltd | ₹506.15 | ₹1,005 cr | 10.5 | — | 12.3% | 10.9% | 0.01 | -4.9% |
| Remus Pharmaceuticals Ltd. | ₹872.95 | ₹994 cr | 27.8 | 2.9 | 12.2% | 14.7% | 0.08 | +28.7% |
Compare BAFNAPH with KOPRAN in detail →
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open BAFNAPH in TickerKhoj →